stockrowHarvard Bioscience, Inc.
HBIO Healthcare Medical Instruments & Supplies
Harvard Bioscience, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $86.6 million, down 8.06% from fiscal 2024.
- Revenue
- +11.1%
- EPS
- −28.0%
- Free cash flow
- −123.4%
- Total debt
- +5.21%
Quarter to June 2026, against a year earlier
Follow HBIO
Alert me
Harvard Bioscience, Inc. (HBIO) EV/Sales
As of 5 November 2026, Harvard Bioscience, Inc. (HBIO) trades at a EV/Sales of 1.2×. Over the past ten years it has ranged from 0.8× (November 2016) to 17.2× (March 2015); the current reading is higher than 31% of that period. That is below the Medical Instruments & Supplies industry median of 2.8× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.1× | (37.79%) |
| FY2024 | 1.7× | (27.35%) |
| FY2023 | 2.3× | 71.84% |
| FY2022 | 1.4× | (50.50%) |
| FY2021 | 2.7× | 35.80% |
| FY2020 | 2.0× | 45.38% |
| FY2019 | 1.4× | (0.81%) |
| FY2018 | 1.4× | (10.90%) |
| FY2017 | 1.6× | 52.48% |
| FY2016 | 1.0× | (13.18%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.0× | 5.57% |
| Mar 2026 | 1.0× | (5.55%) |
| Dec 2025 | 1.1× | 13.37% |
| Sep 2025 | 0.9× | 1.10% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| DXR Daxor Corporation compare | −12.5× |
| RVP Retractable Technologies, Inc. compare | −0.7× |
| BNGO Bionano Genomics, Inc. compare | 0.7× |
| POCI Precision Optics Corp. compare | 1.1× |
| HBIO Harvard Bioscience, Inc. | 1.2× |
| NEPH Nephros Inc. compare | 1.4× |
| MLSS Milestone Scientific, Inc. compare | 2.8× |
| ZTEKF Zentek Ltd. compare | 259× |
| DAVI Davion Healthcare PLC compare | — |
| Medical Instruments & Supplies industry median | 2.8× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)